3.23.1 html 121 270 1 false 53 0 false 6 false false R1.htm 100000 - Document - Cover Page Sheet http://ars-pharma.com/20230331/taxonomy/role/CoverPage Cover Page Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://ars-pharma.com/20230331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://ars-pharma.com/20230331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://ars-pharma.com/20230331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://ars-pharma.com/20230331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://ars-pharma.com/20230331/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 6 false false R7.htm 100080 - Statement - Condensed Statements of Cash Flows Sheet http://ars-pharma.com/20230331/taxonomy/role/CondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 7 false false R8.htm 100090 - Statement - Condensed Statements of Cash Flows (Parenthetical) Sheet http://ars-pharma.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsParenthetical Condensed Statements of Cash Flows (Parenthetical) Statements 8 false false R9.htm 100100 - Disclosure - Nature of Business Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureNatureOfBusiness Nature of Business Notes 9 false false R10.htm 100110 - Disclosure - Summary of Significant Accounting Policies Sheet http://ars-pharma.com/20230331/taxonomy/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 100120 - Disclosure - Merger and Related Transactions Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureMergerAndRelatedTransactions Merger and Related Transactions Notes 11 false false R12.htm 100130 - Disclosure - Fair Value Measurements Sheet http://ars-pharma.com/20230331/taxonomy/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 100140 - Disclosure - Balance Sheet Details Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 13 false false R14.htm 100150 - Disclosure - Collaboration and Out-Licensing Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureCollaborationAndOutlicensing1 Collaboration and Out-Licensing Notes 14 false false R15.htm 100160 - Disclosure - Commitments and Contingencies Sheet http://ars-pharma.com/20230331/taxonomy/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 100170 - Disclosure - In-Licensing and Supply Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureInlicensingAndSupply In-Licensing and Supply Notes 16 false false R17.htm 100180 - Disclosure - Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) (Deficit) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureConvertablePreferredStockAndCommonStockAndStockholdersequityDeficitDeficit Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) (Deficit) Notes 17 false false R18.htm 100220 - Disclosure - Stockholders' Equity (Deficit) Sheet http://ars-pharma.com/20230331/taxonomy/role/StockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 18 false false R19.htm 100230 - Disclosure - Stock-Based Compensation Sheet http://ars-pharma.com/20230331/taxonomy/role/StockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 100250 - Disclosure - Employee Benefit Plans Sheet http://ars-pharma.com/20230331/taxonomy/role/EmployeeBenefitPlans Employee Benefit Plans Notes 20 false false R21.htm 100290 - Disclosure - Related-Party Transactions Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureRelatedpartyTransactions Related-Party Transactions Notes 21 false false R22.htm 100300 - Disclosure - Summary of Significant Accounting Policies (Polices) Sheet http://ars-pharma.com/20230331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolices Summary of Significant Accounting Policies (Polices) Policies http://ars-pharma.com/20230331/taxonomy/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 100310 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://ars-pharma.com/20230331/taxonomy/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 100320 - Disclosure - Fair Value Measurements (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://ars-pharma.com/20230331/taxonomy/role/FairValueMeasurements 24 false false R25.htm 100330 - Disclosure - Balance Sheet Details (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://ars-pharma.com/20230331/taxonomy/role/DisclosureBalanceSheetDetails 25 false false R26.htm 100340 - Disclosure - Collaboration and Out-Licensing (Table) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureCollaborationAndOutlicensingTable Collaboration and Out-Licensing (Table) Tables http://ars-pharma.com/20230331/taxonomy/role/DisclosureCollaborationAndOutlicensing1 26 false false R27.htm 100350 - Disclosure - Commitments and Contingencies (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://ars-pharma.com/20230331/taxonomy/role/CommitmentsAndContingencies 27 false false R28.htm 100380 - Disclosure - Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureConvertablePreferredStockAndCommonStockAndStockholdersequityDeficitTables Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) (Tables) Tables http://ars-pharma.com/20230331/taxonomy/role/DisclosureConvertablePreferredStockAndCommonStockAndStockholdersequityDeficitDeficit 28 false false R29.htm 100390 - Disclosure - Stockholders' Equity (Deficit) (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/StockholdersEquityDeficitTables Stockholders' Equity (Deficit) (Tables) Tables http://ars-pharma.com/20230331/taxonomy/role/StockholdersEquityDeficit 29 false false R30.htm 100400 - Disclosure - Stock-Based Compensation (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://ars-pharma.com/20230331/taxonomy/role/StockBasedCompensation 30 false false R31.htm 100410 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://ars-pharma.com/20230331/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables 31 false false R32.htm 100430 - Disclosure - Nature of Business - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail Nature of Business - Additional Information (Detail) Details 32 false false R33.htm 100440 - Disclosure - Summary of Significant Accounting Policies (Additional Information) (Details) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies (Additional Information) (Details) Details http://ars-pharma.com/20230331/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 100450 - Disclosure - Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail Summary of Significant Accounting Policies - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail) Details 34 false false R35.htm 100460 - Disclosure - Merger and Related Transactions - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureMergerAndRelatedTransactionsAdditionalInformationDetail Merger and Related Transactions - Additional Information (Detail) Details 35 false false R36.htm 100470 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 36 false false R37.htm 100480 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 37 false false R38.htm 100490 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail Balance Sheet Details - Schedule of Prepaid Expenses and Other Current Assets (Detail) Details 38 false false R39.htm 100500 - Disclosure - Balance Sheet Details - Schedule of Property and equipment (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentDetail Balance Sheet Details - Schedule of Property and equipment (Detail) Details 39 false false R40.htm 100510 - Disclosure - Balance Sheet Details - Schedule of Other Assets (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfOtherAssetsDetail Balance Sheet Details - Schedule of Other Assets (Detail) Details 40 false false R41.htm 100520 - Disclosure - Balance Sheet Details - Schedule of Accounts payable and accrued liabilities (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccountsPayableAndAccruedLiabilitiesDetail Balance Sheet Details - Schedule of Accounts payable and accrued liabilities (Detail) Details 41 false false R42.htm 100530 - Disclosure - Collaboration and Out-Licensing - Additional Information (Details) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureCollaborationAndOutlicensingAdditionalInformationDetails Collaboration and Out-Licensing - Additional Information (Details) Details 42 false false R43.htm 100540 - Disclosure - Collaboration and Out-Licensing - Schedule of Reconciliation of Contract Liability from Collaboration Agreements (Details) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureCollaborationAndOutlicensingScheduleOfReconciliationOfContractLiabilityFromCollaborationAgreementsDetails Collaboration and Out-Licensing - Schedule of Reconciliation of Contract Liability from Collaboration Agreements (Details) Details 43 false false R44.htm 100550 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 44 false false R45.htm 100560 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumNoncancelableOperatingLeasePaymentsDetail Commitments and Contingencies - Summary of Future Minimum Noncancelable Operating Lease Payments (Detail) Details 45 false false R46.htm 100570 - Disclosure - In-Licensing and Supply - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureInlicensingAndSupplyAdditionalInformationDetail In-Licensing and Supply - Additional Information (Detail) Details 46 false false R47.htm 100580 - Disclosure - Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) - Summary of common stock reserved for Future Issuance (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureConvertablePreferredStockAndCommonStockAndStockholdersequityDeficitSummaryOfCommonStockReservedForFutureIssuanceDetail Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) - Summary of common stock reserved for Future Issuance (Detail) Details http://ars-pharma.com/20230331/taxonomy/role/DisclosureConvertablePreferredStockAndCommonStockAndStockholdersequityDeficitTables 47 false false R48.htm 100590 - Disclosure - Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) - Additional Information (Details) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureConvertablePreferredStockAndCommonStockAndStockholdersequityDeficitAdditionalInformationDetails Convertable Preferred Stock and Common Stock and Stockholders'Equity (Deficit) - Additional Information (Details) Details http://ars-pharma.com/20230331/taxonomy/role/DisclosureConvertablePreferredStockAndCommonStockAndStockholdersequityDeficitTables 48 false false R49.htm 100600 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/AccruedExpensesSummaryOfAccruedExpensesDetail Accrued Expenses - Summary of Accrued Expenses (Detail) Details 49 false false R50.htm 100620 - Disclosure - Leases - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 50 false false R51.htm 100640 - Disclosure - Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future Issuance (Detail) Details http://ars-pharma.com/20230331/taxonomy/role/StockholdersEquityDeficitTables 51 false false R52.htm 100660 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail) Details 52 false false R53.htm 100670 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfActivityRelatedToStockOptionDetail Stock-Based Compensation - Summary of Activity Related to Stock Option (Detail) Details 53 false false R54.htm 100680 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail) Details 54 false false R55.htm 100690 - Disclosure - Stock Based Compensation - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/StockBasedCompensationAdditionalInformationDetail Stock Based Compensation - Additional Information (Detail) Details 55 false false R56.htm 100710 - Disclosure - Employee Benefit Plans (Additional Information) (Details) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails Employee Benefit Plans (Additional Information) (Details) Details http://ars-pharma.com/20230331/taxonomy/role/EmployeeBenefitPlans 56 false false R57.htm 100720 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail) Details 57 false false R58.htm 100760 - Disclosure - Related-Party Transactions - Additional Information (Detail) Sheet http://ars-pharma.com/20230331/taxonomy/role/DisclosureRelatedpartyTransactionsAdditionalInformationDetail Related-Party Transactions - Additional Information (Detail) Details 58 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. spry-20230331.htm 953 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. spry-20230331.htm 1208 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. spry-20230331.htm 1219 spry-20230331.htm spry-20230331.xsd spry-20230331_cal.xml spry-20230331_def.xml spry-20230331_lab.xml spry-20230331_pre.xml spry-ex31_1.htm spry-ex31_2.htm spry-ex32_1.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true